AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04877912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Abbreviated Scan
Description: All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible.
Study NCT04877912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abbreviated MRI Scan
Description: All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible.
Study NCT02890381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID cp ΔM2-2 Vaccine
Description: 10\^5 plaque-forming units (PFUs); administered as nose drops
Study NCT02890381 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent, administered as nose drops
Study NCT04813341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
Study NCT04813341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week.
Study NCT01099319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renalof
Description: One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
Study NCT01099319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) every 8 hours, for 6 months
Study NCT03702829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotersen
Description: Open Label Study
Study NCT02371369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Each capsule contains 200 mg of pexidartinib for oral administration
Study NCT02371369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule matching pexidartinib capsule for oral administration
Study NCT02371369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule matching pexidartinib capsule for oral administration
Study NCT03598504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable EMG/Vibration device
Description: The device is a combination of an EMG recorder/detector and a vibrator
Study NCT00439777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Study NCT00439777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin overlapping with and followed by VKA
Description: Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Study NCT01012882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sublingual immunotherapy with allergen extract
Description: sublingual application
Study NCT01012882 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: sublingual immunotherapy with placebo
Description: sublingual application
Study NCT01746823 — intervention group
Intervention type: DRUG
Intervention: Cyclosporins
Study NCT03607383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Rice Yeast Extract
Description: adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
Study NCT03607383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
Study NCT00661492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
Study NCT00661492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100mg will be given once daily for 12 weeks.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide placebo
Description: Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide placebo
Description: Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin placebo
Description: Sitagliptin-placebo be given once daily for 12 weeks.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin placebo
Description: Sitagliptin-placebo be given once daily for 12 weeks.
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide placebo
Description: Exenatide-placebo (saline) will be administered intravenously
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide placebo
Description: Exenatide-placebo (saline) will be administered intravenously
Study NCT01744236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-NMMA
Study NCT02817451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
Description: 0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
Study NCT00619021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
Study NCT01601301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECICE System
Description: Lenthening of either the tibia or femur with the PRECICE System.
Study NCT02151162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids pills
Description: Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
Study NCT02151162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids pills
Description: Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
Study NCT02151162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation leaflet
Description: Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
Study NCT02151162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
Study NCT00116376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEE788
Study NCT01573182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Description: VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
Study NCT00002934 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: long-term screening
Study NCT02288429 — intervention group
Intervention type: DRUG
Intervention: colistimethate sodium
Study NCT03790891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-TriCAR-T/SILK
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
Study NCT02410395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
Study NCT02410395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified
Description: The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
Study NCT00804310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
Study NCT00804310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
Study NCT03941808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glisodin tablet
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Study NCT03941808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Study NCT03392727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Box
Description: Baby box (bassinet) with infant items
Study NCT03392727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Community Box
Description: Baby box (bassinet)
Study NCT03392727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Session
Description: Face to face education and baby box orientation session
Study NCT03392727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Education
Description: Online baby box education
Study NCT02747108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Test Group Intervention
Description: Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
Study NCT02747108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure Group Intervention
Description: Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
Study NCT02042508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening
Study NCT01888159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Salpingectomy
Study NCT01888159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal sterilization with bipolar energy
Study NCT05886283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted.
Study NCT05886283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: utrasound phacoemulsification
Description: US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
Study NCT05886283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nanolaser phacoemulsification
Description: Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
Study NCT02042508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid training programme
Study NCT02571478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marriage Checkup
Description: The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
Study NCT03740178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4334
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Study NCT03740178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-4334
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Study NCT03740178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepepzil
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
Study NCT03740178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepepzil
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
Study NCT03983369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
Study NCT03983369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00660517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP29-02
Description: azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
Study NCT00660517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine Hcl
Description: azelastine Hcl nasal spray one spray per nostril two times a day
Study NCT00660517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
Study NCT00660517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo nasal spray one spray per nostril two times a day
Study NCT00593099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
Study NCT00593099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules (PLA) containing only a dextrose matrix.
Study NCT00400374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
Study NCT00400374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib, 400 mg, daily for 6 months.
Study NCT01863667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Study NCT01863667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
Study NCT01863667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin Placebo
Description: Matching placebo to omarigliptin capsule administered orally once weekly
Study NCT01863667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Placebo
Description: Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal